

Gary R Matzke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11359400/publications.pdf>

Version: 2024-02-01

77
papers

2,911
citations

201658

27
h-index

168376

53
g-index

79
all docs

79
docs citations

79
times ranked

2410
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 62, 365-376.	4.7	219
2	Liver disease selectively modulates cytochrome P450-mediated metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 235-245.	4.7	203
3	Analgesics and the kidney: Summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc Committee of the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , 1996, 27, 162-165.	1.9	181
4	Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis. <i>Pharmacotherapy</i> , 2009, 29, 562-577.	2.6	157
5	Pharmacokinetics of cefepime in subjects with renal insufficiency. <i>Clinical Pharmacology and Therapeutics</i> , 1990, 48, 268-276.	4.7	129
6	Validity of creatinine clearance estimates in the assessment of renal function. <i>Clinical Pharmacology and Therapeutics</i> , 1990, 48, 503-508.	4.7	112
7	Hepatic drug metabolism and transport in patients with kidney disease. <i>American Journal of Kidney Diseases</i> , 2003, 42, 906-925.	1.9	103
8	A Primer on Continuous Renal Replacement Therapy for Critically Ill Patients. <i>Annals of Pharmacotherapy</i> , 1998, 32, 362-375.	1.9	100
9	Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. <i>Clinical Pharmacology and Therapeutics</i> , 1988, 43, 63-71.	4.7	78
10	Controlled Comparison of Gentamicin and Tobramycin Nephrotoxicity. <i>American Journal of Nephrology</i> , 1983, 3, 11-17.	3.1	77
11	Drug Administration in Patients with Renal Insufficiency Minimising Renal and Extrarenal Toxicity. <i>Drug Safety</i> , 1997, 16, 205-231.	3.2	77
12	Impact of a pharmacist-physician collaborative care model on patient outcomes and health services utilization. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 1039-1047.	1.0	69
13	Evaluation of Renal Drug Dosing: Prescribing Information and Clinical Pharmacist Approaches. <i>Pharmacotherapy</i> , 2010, 30, 776-786.	2.6	66
14	Evaluation of the Influence of Diabetes Mellitus on Antipyrine Metabolism and CYP1A2 and CYP2D6 Activity. <i>Pharmacotherapy</i> , 2000, 20, 182-190.	2.6	58
15	Antimicrobial Treatment of Peritonitis Associated with Continuous Ambulatory Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 1991, 11, 252-260.	2.3	51
16	Disposition of vancomycin during hemofiltration. <i>Clinical Pharmacology and Therapeutics</i> , 1986, 40, 425-429.	4.7	50
17	Medication knowledge and compliance among patients receiving long-term dialysis. <i>American Journal of Health-System Pharmacy</i> , 1995, 52, 1895-1900.	1.0	49
18	Medication adherence challenges among patients experiencing homelessness in a behavioral health clinic. <i>Research in Social and Administrative Pharmacy</i> , 2015, 11, e110-e120.	3.0	49

#	ARTICLE	IF	CITATIONS
19	The pharmacodynamics of intravenous and oral torsemide in patients with chronic renal insufficiency. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 56, 39-47.	4.7	46
20	Protein Binding of Disopyramide and Elevated Alpha-1-Acid Glycoprotein Concentrations in Serum Obtained from Dialysis Patients and Renal Transplant Recipients. <i>American Journal of Nephrology</i> , 1985, 5, 35-39.	3.1	42
21	Determinants of Ceftriaxone Clearance by Continuous Venovenous Hemofiltration and Hemodialysis. <i>Pharmacotherapy</i> , 2000, 20, 635-643.	2.6	41
22	Determinants of Ceftazidime Clearance by Continuous Venovenous Hemofiltration and Continuous Venovenous Hemodialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 1639-1644.	3.2	41
23	Integration of collaborative medication therapy management in a safety net patient-centered medical home. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2011, 51, 167-172.	1.5	40
24	The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 56, 31-38.	4.7	36
25	Nonrenal toxicities of acetaminophen, aspirin, and nonsteroidal anti-inflammatory agents. <i>American Journal of Kidney Diseases</i> , 1996, 28, S63-S70.	1.9	34
26	Use of Chlorzoxazone as an In Vivo Probe of Cytochrome P450 2E1: Choice of Dose and Phenotypic Trait Measure. <i>Journal of Clinical Pharmacology</i> , 1998, 38, 82-89.	2.0	34
27	Cefotaxime and desacetyl cefotaxime kinetics in renal impairment. <i>Clinical Pharmacology and Therapeutics</i> , 1985, 38, 31-36.	4.7	27
28	Gentamicin Disposition in Young and Elderly Patients with Various Degrees of Renal Function. <i>Journal of Clinical Pharmacology</i> , 1987, 27, 216-220.	2.0	24
29	Characterization of tubular functional capacity in humans using para-aminohippurate and famotidine. <i>Kidney International</i> , 2001, 59, 295-303.	5.2	19
30	Effect of Conjugated Equine Estrogens on Oxidative Metabolism in Middle-aged and Elderly Postmenopausal Women. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 1299-1307.	2.0	19
31	Effects of liver disease on the disposition of the opioid antagonist nalmeferne*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 61, 15-23.	4.7	18
32	Status of Hemodialysis of Drugs in 2002. <i>Journal of Pharmacy Practice</i> , 2002, 15, 405-418.	1.0	18
33	An In Vivo In Vitro Study of Cefepime and Cefazolin Dialytic Clearance During High-Flux Hemodialysis. <i>Pharmacotherapy</i> , 2008, 28, 977-983.	2.6	18
34	Influence of Continuous Venovenous Hemofiltration and Continuous Venovenous Hemodiafiltration on the Disposition of Doripenem. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1187-1193.	3.2	18
35	Gentamicin and Tobramycin Dosing Guidelines: An Evaluation. <i>Drug Intelligence & Clinical Pharmacy</i> , 1983, 17, 425-432.	0.4	17
36	Disposition of Minoxidil in Patients with Various Degrees of Renal Function. <i>Journal of Clinical Pharmacology</i> , 1989, 29, 798-802.	2.0	16

#	ARTICLE	IF	CITATIONS
37	Comparison of Iothalamate Clearance Methods for Measuring GFR. <i>Pharmacotherapy</i> , 1999, 19, 943-950.	2.6	16
38	Suprofen-Induced Uricosuria. <i>American Journal of Nephrology</i> , 1988, 8, 90-95.	3.1	15
39	The Effect of Renal Insufficiency and Hemodialysis on the Pharmacokinetics of Nalmefene. <i>Journal of Clinical Pharmacology</i> , 1996, 36, 144-151.	2.0	15
40	Influence of kidney disease on drug disposition: An assessment of industry studies submitted to the FDA for new chemical entities 1999-2010. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 390-398.	2.0	14
41	Clinical Pharmacokinetics 1990. <i>Clinical Pharmacokinetics</i> , 1990, 18, 1-19.	3.5	10
42	Pharmacotherapeutic Consequences of Recent Advances in Hemodialysis Therapy. <i>Annals of Pharmacotherapy</i> , 1994, 28, 512-514.	1.9	9
43	Impaired 6-hydroxychlorzoxazone elimination in patients with kidney disease: implication for cytochrome P450 2E1 pharmacogenetic studies. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 555-568.	4.7	9
44	The ADAPT online education program: A tool for practicing pharmacists delivering patient-centered care. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2017, 57, 601-607.	1.5	9
45	Development and Implementation of an Academic-Community Partnership to Enhance Care among Homeless Persons. <i>Innovations in Pharmacy</i> , 2011, 2, 1-7.	0.6	9
46	Disposition of Guanadrel in Subjects with Normal and Impaired Renal Function. <i>Journal of Clinical Pharmacology</i> , 1989, 29, 128-132.	2.0	8
47	Disposition of antipyrine and acetaminophen given alone and in combination to human subjects. <i>Pharmaceutical Research</i> , 1990, 07, 204-207.	3.5	8
48	Evaluation of Three Gentamicin Serum Assay Techniques. <i>Therapeutic Drug Monitoring</i> , 1982, 4, 195-200.	2.0	7
49	Effect of renal insufficiency on CYP activity.. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 155-155.	4.7	7
50	Nephrology Pharmaceutical Care Preceptorship: A Programmatic and Clinical Outcomes Assessment. <i>Annals of Pharmacotherapy</i> , 2000, 34, 593-599.	1.9	7
51	Health-Care Reform 2010: How Will It Impact You and Your Practice?. <i>Annals of Pharmacotherapy</i> , 2010, 44, 1485-1491.	1.9	7
52	Pharmacokinetics of abecarnil in patients with renal insufficiency*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 520-528.	4.7	6
53	A Novel Education and Training Program to Enhance Student Advocacy. <i>American Journal of Pharmaceutical Education</i> , 2015, 79, 95.	2.1	6
54	Improving Health of At-Risk Rural Patients project: A collaborative care model. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 1760-1768.	1.0	6

#	ARTICLE	IF	CITATIONS
55	Protein Binding of Phenytoin, <i>p</i> -Hydroxy Phenytoin, and <i>p</i> -Hydroxy Phenytoin Glucuronide. <i>Journal of Clinical Pharmacology</i> , 1986, 26, 677-679.	2.0	5
56	Health Care Reform 2011: Opportunities for Pharmacists. <i>Annals of Pharmacotherapy</i> , 2012, 46, 27S-32S.	1.9	5
57	Population health and medicine: Policy and financial drivers. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 1413-1421.	1.0	5
58	Effect of quinidine on serum digoxin concentrations. <i>American Journal of Health-System Pharmacy</i> , 1979, 36, 968-971.	1.0	4
59	Heparin Interferes with Tobramycin Serum Concentration Determinations by Emit. <i>Drug Intelligence & Clinical Pharmacy</i> , 1984, 18, 517-519.	0.4	4
60	Clinical Pharmacokinetics of Anti-Infectives. , 1992, , 627-642.		4
61	Effects of Hemodialysis on Plasma Protein Binding of Bepridil. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 137-141.	2.0	3
62	Clinical Consequences of Nonnarcotic Analgesic Use. <i>Annals of Pharmacotherapy</i> , 1997, 31, 245-248.	1.9	3
63	Health-Care Policy 2011: Implications for Pharmacists. <i>Annals of Pharmacotherapy</i> , 2011, 45, 412-413.	1.9	3
64	Doripenem Dosing Recommendations for Critically Ill Patients Receiving Continuous Renal Replacement Therapy. <i>ISRN Pharmacology</i> , 2012, 2012, 1-10.	1.6	3
65	Life on Capitol Hill: A pharmacist's perspective. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 725-730.	1.0	2
66	Antifungal, Antitubercular, and Antiviral Agents. <i>Seminars in Dialysis</i> , 1988, 1, 170-173.	1.3	2
67	The relationship between medication-related problems and behavioural health condition among patients served by a health care for the homeless centre. <i>Journal of Pharmaceutical Health Services Research</i> , 2012, 3, 173-178.	0.6	2
68	Pharmacist participation in health policy development. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 107-107.	1.0	2
69	Doses of histamine-2-receptor antagonists should be reduced in patients with low glomerular filtration rate. <i>Nature Clinical Practice Nephrology</i> , 2006, 2, 298-299.	2.0	1
70	Chapter 8. Citizens First: A Pharmacist's Civic Responsibility. , 2014, , .		1
71	Nephropathy as a hazard of analgesic abuse. <i>American Journal of Health-System Pharmacy</i> , 1981, 38, 1536-1540.	1.0	0
72	Documenting the influence of clinical pharmacists. <i>American Journal of Health-System Pharmacy</i> , 1982, 39, 481-482.	1.0	0

#	ARTICLE	IF	CITATIONS
73	Antibiotics: Antianaerobic Agents, Quinolones, and Tetracyclines. <i>Seminars in Dialysis</i> , 1988, 1, 220-223.	1.3	0
74	Antibiotics: Vancomycin. <i>Seminars in Dialysis</i> , 1989, 2, 54-55.	1.3	0
75	Executive Summary: The Virginia Commonwealth University Pharmacy Practice Transformation Conference. <i>Annals of Pharmacotherapy</i> , 2012, 46, 1S-11S.	1.9	0
76	Principles of Drug Therapy in Patients with Reduced Kidney Function. , 2014, , 337-345.		0
77	Principles of Drug Therapy in Patients with Reduced Kidney Function. , 2009, , 322-329.		0